Literature DB >> 14564330

Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure.

Richard Isnard1, Françoise Pousset, Olga Chafirovskaïa, Alain Carayon, Jean Sébastien Hulot, Daniel Thomas, Michel Komajda.   

Abstract

BACKGROUND: Peak oxygen consumption is a cornerstone for prognostic determination in patients with congestive heart failure. The purpose of this study was to assess whether plasma B-type natriuretic peptide (BNP) provided any additional prognostic information.
METHODS: Plasma concentrations of atrial natriuretic peptide, N terminal pro-atrial natriuretic peptide, BNP, endothelin-1, norepinephrine, and peak VO2 were measured in 250 consecutive outpatients with mild to moderate heart failure (96% in New York Heart Association [NYHA] class II or III) and left ventricular ejection fraction (LVEF) <45%.
RESULTS: During a median follow-up of 584 days, 42 patients died (19 from sudden death) and 5 underwent urgent heart transplantation. Multivariate stepwise regression analysis showed that, among 13 variables including NYHA and LVEF, plasma BNP (chi2 = 11.9, P =.0001) was the strongest independent predictor of death or urgent transplantation, followed by serum sodium (chi2 = 8, P =.0046), resting heart rate (chi2 = 7.5, P =.0062), plasma endothelin-1 (chi2 = 7.2, P =.007), and peak VO2 (chi2 = 6.2, P =.012). Patients with plasma BNP above the upper quartile value (260 pg/mL) had a 1-year rate of death or urgent transplantation of 31%. The 1- and 2-year survival rates without urgent transplantation in patients with a peak VO2 < or =14 mL x kg(-1) x min(-1) were 71% and 59%, respectively, when plasma BNP was >137 pg/mL (median value), compared with 100% and 89%, respectively, when plasma BNP was < or =137 pg/mL (P =.008). Furthermore, plasma BNP was the only independent predictor of sudden death (chi2 = 19.9, P =.00001).
CONCLUSIONS: Plasma BNP provides additive independent prognostic information compared to peak VO2 alone in outpatients with mild to moderate heart failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14564330     DOI: 10.1016/S0002-8703(03)00365-X

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable?

Authors:  Marco P Donadini; Alessandro Squizzato; Francesco Dentali; Walter Ageno
Journal:  Intern Emerg Med       Date:  2009-04-09       Impact factor: 3.397

Review 2.  How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review.

Authors:  Jenny A Doust; Eva Pietrzak; Annette Dobson; Paul Glasziou
Journal:  BMJ       Date:  2005-03-19

3.  Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies.

Authors:  A Verma; F Kilicaslan; D O Martin; S Minor; R Starling; N F Marrouche; S Almahammed; O M Wazni; S Duggal; R Zuzek; H Yamaji; J Cummings; M K Chung; P J Tchou; A Natale
Journal:  Heart       Date:  2005-05-27       Impact factor: 5.994

Review 4.  Diagnosis and treatment of depression in patients with congestive heart failure: a review of the literature.

Authors:  James K Rustad; Theodore A Stern; Kathy A Hebert; Dominique L Musselman
Journal:  Prim Care Companion CNS Disord       Date:  2013-08-15

5.  Prognostic value of brain natriuretic peptide and enhanced ventilatory response to exercise in patients with chronic heart failure.

Authors:  Angela Beatrice Scardovi; Renata De Maria; Andrea Celestini; Claudio Coletta; Nadia Aspromonte; Silvia Perna; Marina Parolini; Roberto Ricci
Journal:  Intern Emerg Med       Date:  2008-06-17       Impact factor: 3.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.